Evidence map›Paper›PMID 41706540›Full record

ArticleArthritis care & research2026

Rheumatologic Manifestations of Patients With Type B Insulin Resistance.

S Amara Ogbonnaya, Sandra G Williams, Raphael A Kirou, Marissa Lightbourne, Rebecca J Brown

Abstract read
In one paragraph

Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

S Amara OgbonnayaNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID https://orcid.org/0009-0003-8924-3999
Sandra G WilliamsNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Raphael A KirouNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID https://orcid.org/0000-0001-6481-4810
Marissa LightbourneNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland.
Rebecca J BrownNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland.ORCID https://orcid.org/0000-0002-2589-7382

Funding

Molecular and Clinical Studies of Insulin ResistanceZ01DK047050 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GORDEN, PHILLIP · 2007 to 2008
$653k
Intramural NIH HHS Z01 DK047050NIDDK NIH HHS ZIA- DK047050-19
6 · The paper itself

Abstract

objectiveThe objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life-threatening condition.

methodsThirty-eight patients with TBIR who were seen at the National Institutes of Health between 1976 and 2024 were included. Retrospective chart review was performed to assign primary rheumatologic diagnoses, characterize endocrinologic laboratory measurements, and identify clinical and laboratory manifestations of SLE, including hypocomplementemia, cytopenias, and autoantibody seropositivity.

resultsSLE was the most frequent underlying diagnosis (81.5%); one patient each had Sjögren disease and primary biliary cholangitis. Patients were predominantly female (89.5%) and Black/African American (84.2%). The median Systemic Lupus Erythematosus Disease Activity Index 2000 score was 14 (interquartile range 7). High or very high U1 RNP autoantibodies were seen in >50% of patients. TBIR was associated with a high prevalence of acute neuropathies of the seventh and/or eighth cranial nerve (18.4%), angioedema (10.5%), and uveitis (5%).

conclusionTBIR can be a rare complication of SLE, is associated with the presence of high-titer U1 RNP autoantibodies, and may co-occur with other rare SLE manifestations.

Indexed as

Insulin ResistanceLupus Erythematosus, SystemicAdultAutoantibodiesFemaleHumansMaleMiddle AgedReceptor, InsulinRetrospective StudiesRheumatic DiseasesAutoantibodiesReceptor, Insulin

Identifiers

PMID41706540
PMCPMC13511296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.